A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair folliclecell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
HairClone is offering a DermalPapillaCell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.
Japanese scientists discovered ABM cells, enabling successful human hair follicle cloning, potentially curing hair loss. The treatment may be available in Japan by 2028, but it will be expensive and require travel.
AMP-303 and AMP-601 are new hair loss treatments targeting dermalpapillacells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.